References:
- Smith PF, Dodds M, Bentley D, et al. Dosing will be a key success
factor in repurposing antivirals for COVID‐19. Br J Clin
Pharmacol . 2020 Apr 17. doi: 10.1111/bcp.14314
- Caly L, Druce JD, Catton MG, et al. The FDA approved Drug Ivermectin
inhibits the replication of SARS-CoV-2 in vitro. Antivir Res2020 https://doi.org/10.1016/j.antiviral.2020.104787.
- Wagstaff KM, Rawlinson SM, Hearps AC, et al. An AlphaScreen®-based
assay for high-throughput screening for specific inhibitors of nuclear
import. J Biomol Screen 2011; 16(2): 192-200
- Weil GJ, Bogus J, Christian M, et al. The safety of double- and
triple-drug community mass drug administration for lymphatic
filariasis: A multicenter, open-label, cluster-randomized study.PLoS Med 2019;16(6):e1002839.
- Guzzo CA, Furtek CI, Porras AG, et al. Safety, tolerability, and
pharmacokinetics of escalating high doses of ivermectin in healthy
adult subjects. J Clin Pharmacol 2002; 42(10): 1122-1133.
- U.S. Package Circular: STROMECTOL® (ivermectin). Whitehouse Station,
NJ: Merck & Co., Inc., 1998.